10:23:49 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-08-30 Kvartalsrapport 2024-Q2
2024-05-02 Ordinarie utdelning BONEH 0.00 EUR
2024-04-30 Årsstämma 2024
2024-02-26 Bokslutskommuniké 2023
2023-10-23 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-02 Ordinarie utdelning BONEH 0.00 EUR
2023-04-28 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning BONEH 0.00 EUR
2022-04-28 Årsstämma 2022
2022-03-17 Extra Bolagsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-04-29 Ordinarie utdelning BONEH 0.00 EUR
2021-04-28 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-08-31 Kvartalsrapport 2020-Q2
2020-04-06 Ordinarie utdelning BONEH 0.00 EUR
2020-04-05 Årsstämma 2020
2020-03-20 Bokslutskommuniké 2019
2019-08-30 Kvartalsrapport 2019-Q2
2019-04-08 Ordinarie utdelning BONEH 0.00 EUR
2019-04-05 Årsstämma 2019
2018-08-30 Kvartalsrapport 2018-Q2
2018-03-29 Årsstämma 2018

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
BBS-Bioactive Bone Substitutes är verksamt inom medicinteknik. Bolaget designar, utvecklar och konstruerar biologiska implantat för patienter med benfel och läkningsbesvär. Bolagets lösningar vidaresäljs under varumärket Artebone och baseras på tricalciumfosfat (TCP) och benprotein, som stimulerar benläkningsprocessen. Bolaget grundades under 2003 och har sitt huvudkontor i Oulu.
2022-08-31 15:00:00

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 31 August 2022 16.00 (CEST)

BBS Bioactive Bone Substitutes Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Paananen, Ahti

Position: Member of the Board/Deputy member

Issuer: BBS Bioactive Bone Substitutes Oyj

LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION

Reference number: 743700BYSBP0PCR6N767_20220826083437_4

____________________________________________

Transaction date: 2022-06-17

Venue not applicable

Instrument type: SHARE

ISIN: FI4000260583

Nature of the transaction: SUBSCRIPTION

Transaction details

(1): Volume: 166,689 Unit price: 1.3 EUR

Aggregated transactions

(1): Volume: 166,689 Volume weighted average price: 1.3 EUR

____________________________________________

Transaction date: 2022-06-20

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522909

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

Transaction details

(1): Volume: 20,836 Unit price:  EUR

Aggregated transactions

(1): Volume: 20,836 Volume weighted average price:  EUR

____________________________________________

Transaction date: 2022-06-20

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522891

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

Transaction details

(1): Volume: 20,836 Unit price:  EUR

Aggregated transactions

(1): Volume: 20,836 Volume weighted average price:  EUR

For more information:

Ilkka Kangasniemi, CEO,
tel. +35840 7080307, e-mail: ilkka.kangasniemi@bbs-artebone.fi

Liisa Hukka, CFO,
tel. +35840 0611038, e-mail: liisa.hukka@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB, tel. +46 70 551 67 29, info@certifiedadviser.se

BBS in brief

BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi.

BBS-Bioactive Bone Substitutes Oyj:n shares have been listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

More information: www.bbs-artebone.fi